SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn
- PMID: 27874994
- PMCID: PMC5401975
- DOI: 10.1111/bcp.13194
SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn
Abstract
Aim: The use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN). Limited data are available on the risk of PPHN associated with serotonin norepinephrine reuptake inhibitors (SNRIs). We aimed to quantify both associations.
Methods: Using data from the Quebec Pregnancy Cohort between 1998 and 2009, we included women covered by the provincial drug plan who had a singleton live birth. Exposure categories were SSRI, SNRI and other antidepressant use; non-users were considered as the reference category. Generalized estimating equation models were used to obtain risk estimates and 95% confidence intervals (CIs). Confounding by indication was minimized by adjusting for history of maternal depression/anxiety before pregnancy.
Results: Overall, 143 281 pregnancies were included; PPHN was identified in 0.2% of newborns. Adjusting for maternal depression, and other potential confounders, SSRI use during the second half of pregnancy was associated with an increased risk of PPHN [adjusted odds ratio (aOR) 4.29, 95% CI 1.34, 13.77] compared with non-use of antidepressants; SNRI use during the same time window was not statistically associated with the risk of PPHN (aOR 0.59, 95% CI 0.06, 5.62). Use of SSRIs and SNRIs before the 20th week of gestation was not associated with the risk of PPHN.
Conclusions: Use of SSRIs in the second half of pregnancy was associated with the risk of PPHN. Given our results on SNRIs and the lack of statistical power for these analyses, it is unclear whether SNRI use during pregnancy also increases the risk of PPHN.
Keywords: Pregnancy; SSRI; depression; persistent pulmonary hypertension of the newborn (PPHN); quebec pregnancy cohort; venlafaxine.
© 2016 The British Pharmacological Society.
Figures
Similar articles
-
Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis.J Womens Health (Larchmt). 2019 Mar;28(3):331-338. doi: 10.1089/jwh.2018.7319. Epub 2018 Nov 8. J Womens Health (Larchmt). 2019. PMID: 30407100 Review.
-
Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.JAMA. 2015 Jun 2;313(21):2142-51. doi: 10.1001/jama.2015.5605. JAMA. 2015. PMID: 26034955 Free PMC article.
-
Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.N Engl J Med. 2006 Feb 9;354(6):579-87. doi: 10.1056/NEJMoa052744. N Engl J Med. 2006. PMID: 16467545
-
Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis.Am J Obstet Gynecol. 2019 Jan;220(1):57.e1-57.e13. doi: 10.1016/j.ajog.2018.08.030. Epub 2018 Aug 28. Am J Obstet Gynecol. 2019. PMID: 30170040
-
Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies.Am J Psychiatry. 2012 Feb;169(2):134-40. doi: 10.1176/appi.ajp.2011.11040553. Am J Psychiatry. 2012. PMID: 22420034 Review.
Cited by
-
Identifying the most critical side effects of antidepressant drugs: a new model proposal with quantum spherical fuzzy M-SWARA and DEMATEL techniques.BMC Med Inform Decis Mak. 2024 Sep 28;24(1):276. doi: 10.1186/s12911-024-02692-z. BMC Med Inform Decis Mak. 2024. PMID: 39342208 Free PMC article.
-
Medicolegal Review: Perinatal Effexor Lawsuits and Legal Strategies Adverse to Prescribing Obstetric Providers.AJP Rep. 2019 Jan;9(1):e88-e91. doi: 10.1055/s-0039-1678723. Epub 2019 Mar 19. AJP Rep. 2019. PMID: 31041117 Free PMC article. Review.
-
Sudden Onset of Severe Pulmonary Hypertension in a Preterm Infant: A Case Report on the Role of Maternal Use of Serotonin Re-Uptake Inhibitors During Pregnancy and Concurrent Risk Factors.Front Pediatr. 2022 Jun 10;10:855419. doi: 10.3389/fped.2022.855419. eCollection 2022. Front Pediatr. 2022. PMID: 35757139 Free PMC article.
-
Effectiveness of patient decision aids in women considering psychotropic medication use during pregnancy: a literature review.Arch Womens Ment Health. 2021 Aug;24(4):569-578. doi: 10.1007/s00737-021-01118-3. Epub 2021 Mar 9. Arch Womens Ment Health. 2021. PMID: 33751206 Review.
-
Advances in Psychotropic Treatment for Pregnant Women: Efficacy, Adverse Outcomes, and Therapeutic Monitoring.J Clin Med. 2024 Jul 27;13(15):4398. doi: 10.3390/jcm13154398. J Clin Med. 2024. PMID: 39124665 Free PMC article. Review.
References
-
- Hageman JR, Adams MA, Gardner TH. Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. Am J Dis Child 1984; 138: 592–595. - PubMed
-
- Abman SH. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl 1999; 18: 201–204. - PubMed
-
- Chambers CD, Hernandez‐Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin‐reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579–587. - PubMed
-
- Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723–1733. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical